Literature DB >> 14047216

SEROLOGICAL RELATIONSHIPS AMONG HUMAN MYCOPLASMAS AS SHOWN BY COMPLEMENT-FIXATION AND GEL DIFFUSION.

D TAYLOR-ROBINSON, N L SOMERSON, H C TURNER, R M CHANOCK.   

Abstract

Taylor-Robinson, David (National Institutes of Health, Bethesda, Md.), Norman L. Somerson, Horace C. Turner, and Robert M. Chanock. Serological relationships among human mycoplasmas as shown by complement-fixation and gel diffusion. J. Bacteriol. 85:1261-1273. 1963.-Antigenic relationships among human mycoplasmas were studied by complement-fixation and agar gel diffusion techniques. Four recognized human species Mycoplasma hominis type 1, M. hominis type 2, M. salivarium, and M. fermentans were antigenically distinct in these tests. In addition, M. pneumoniae (Eaton agent, the etiological agent of cold agglutinin-positive atypical pneumonia) was different from these four species. Although these species were distinct, evidence of shared antigenic components was obtained in complement-fixation and agar gel diffusion tests. Since rabbits were immunized with mycoplasmas grown in rabbit muscle infusion broth supplemented with rabbit serum or, in the case of M. pneumoniae, with infected chick embryo lung suspension, the possibility that the heterologous reactions resulted from antibody to growth medium components could be excluded. Four recent mycoplasma isolates from the oropharynx were analyzed, and three were shown to be closely related to M. hominis type 1, and the fourth was closely related to M. salivarium. Although the recent isolates could not be distinguished from the related "prototype" human species by complement-fixation, differences could be detected by the agar gel diffusion technique.

Entities:  

Keywords:  AGAR; ANTIGEN-ANTIBODY REACTIONS; CHICK EMBRYO; COMPLEMENT FIXATION TESTS; EXPERIMENTAL LAB STUDY; FLUORESCENCE; GUINEA PIGS; IMMUNE SERUMS; MYCOPLASMA; PRECIPITIN TESTS; RABBITS

Mesh:

Substances:

Year:  1963        PMID: 14047216      PMCID: PMC278327          DOI: 10.1128/jb.85.6.1261-1273.1963

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  12 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Hemolyin production as an aid in the identification and quantitation of Eaton agent (Mycoplasma pneumoniae).

Authors:  N L SOMERSON; D TAYLOR-ROBINSON; R M CHANOCK
Journal:  Am J Hyg       Date:  1963-01

3.  Growth of Eaton PPLO in broth and preparation of complement fixing antigen.

Authors:  R M CHANOCK; W D JAMES; H H FOX; H C TURNER; M A MUFSON; L HAYFLICK
Journal:  Proc Soc Exp Biol Med       Date:  1962 Aug-Sep

4.  Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO.

Authors:  R M CHANOCK; L HAYFLICK; M F BARILE
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

5.  Preparation of pleuropneumonia-like organisms for microscopic study.

Authors:  H W CLARK; R C FOWLER; T M BROWN
Journal:  J Bacteriol       Date:  1961-03       Impact factor: 3.490

6.  The classification and nomenclature of organisms of the pleuropneumonia group.

Authors:  D G EDWARD; E A FREUNDT
Journal:  J Gen Microbiol       Date:  1956-02

7.  [Use of dyes in electrophoretic and immuno-electrophoretic analyses in gel media].

Authors:  J URIEL; P GRABAR
Journal:  Ann Inst Pasteur (Paris)       Date:  1956-04

8.  Role of organisms of the pleuropneumonia group in human genital infections.

Authors:  C S NICOL; D G EDWARD
Journal:  Br J Vener Dis       Date:  1953-09

9.  Isolation of a pleuropneumonia-like organism (G-strain) in a case of fusospirillary vulvovaginitis.

Authors:  M RUITER; H M WENTHOLT
Journal:  Acta Derm Venereol       Date:  1953       Impact factor: 4.437

10.  PPLO of human genital origin; serological classification of strains and antibody distribution in man.

Authors:  D H CARD
Journal:  Br J Vener Dis       Date:  1959-03
View more
  48 in total

1.  THE SEROLOGICAL DIFFERENTIATION OF MYCOPLASMA STRAINS (PLEURO-PNEUMONIA-LIKE ORGANISMS) FROM VARIOUS SOURCES.

Authors:  R M LEMCKE
Journal:  J Hyg (Lond)       Date:  1964-06

2.  HEMOLYSIN OF MYCOPLASMA PNEUMONIAE.

Authors:  N L SOMERSON; R H PURCELL; D TAYLOR-ROBINSON; R M CHANOCK
Journal:  J Bacteriol       Date:  1965-03       Impact factor: 3.490

Review 3.  MYCOPLASMA SPECIES OF MAN.

Authors:  L HAYFLICK; R M CHANOCK
Journal:  Bacteriol Rev       Date:  1965-06

4.  Further studies of agents isolated from tissue cultures inoculated with human leukaemic bone-marrow.

Authors:  R J FALLON; N R GRIST; D R INMAN; R M LEMCKE; G NEGRONI; D A WOODS
Journal:  Br Med J       Date:  1965-08-14

5.  Effect of Animal Passage on Arthritogenic and Biological Properties of Mycoplasma arthritidis.

Authors:  L Golightly-Rowland; B C Cole; J R Ward; B B Wiley
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

6.  A staphylococcal radioimmunoassay for detection of antibodies to Mycoplasma pneumoniae.

Authors:  H Brunner; W Schaeg; U Brück; U Schummer; H G Schiefer
Journal:  Med Microbiol Immunol       Date:  1977-05-18       Impact factor: 3.402

7.  Enzootic pneumonia in pigs: identification of a causative mycoplasma in infected pigs and in cultures by immunofluorescent staining.

Authors:  C L'Ecuyer; P Boulanger
Journal:  Can J Comp Med       Date:  1970-01

8.  Adsorption of Mycoplasma pneumoniae to neuraminic acid receptors of various cells and possible role in virulence.

Authors:  O Sobeslavsky; B Prescott; R M Chanock
Journal:  J Bacteriol       Date:  1968-09       Impact factor: 3.490

9.  CYTOPATHOGENIC MYCOPLASMAS ASSOCIATED WITH TWO HUMAN TUMORS. I. ISOLATION AND BIOLOGICAL ASPECTS.

Authors:  D ARMSTRONG; G HENLE; N L SOMERSON; L HAYFLICK
Journal:  J Bacteriol       Date:  1965-08       Impact factor: 3.490

10.  Fate of intravenously injected Mycoplasma arthritidis in rodents and effect of vaccines.

Authors:  B C Cole; J R Ward
Journal:  Infect Immun       Date:  1973-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.